nivolumab,ipilimumab,cabozantinib,sunitinib
bms,pfizer
['nivolumab', 'sunitinib', 'rcc,(-irccs),(-srcc),(-urcc)', 'cabozantinib', 'renal,(-adrenal)', 'cm9er', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'check,mate,9er', 'biomarker', 'cabo ', 'nivo', 'cabo sun', 'bristol', 'marker ']
update on biomarker analysis from #cm9er nivo/cabo vs sunitinib in metastatic rcc by : c-met and pdl1 were not predictive of pfs benefit this will help characterize the tumor microenvironment for those who may best respond to anti-pd1 &amp; anti-vegf in mrcc
#gu23 
GU Oncologist | 🇨🇦 GU & NOLA Heme/Onc Alumni | Interested in GU, Immuno Onc & Med Ed | @ASCO Featured Voice | @TwoOncDocs podcast